IMPAACT: Global HIV care for pregnant people, babies, children, and young people
IMPAACT Leadership Group
This program develops and tests safer, longer-lasting HIV and TB treatments and ways to reach ART-free remission for pregnant and postpartum people, infants, children, and adolescents living with HIV worldwide.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Johns Hopkins University NIH-funded |
| Lab location | 1 site (Baltimore, United States) |
| Project ID | NIH-11457787 on NIH RePORTER |
What this research studies
If you join IMPAACT, you would be part of a global network that runs clinical trials and studies aimed at improving HIV care for pregnant and postpartum people, infants, children, and adolescents. The work includes testing drug dosing, safety, and antiviral effectiveness, collecting samples for pharmacokinetics and other laboratory studies, and studying new strategies to prevent or control HIV without continuous antiretroviral therapy. IMPAACT also studies tuberculosis prevention, diagnosis, and treatment in people with and without HIV in these same populations. Trials are carried out across multiple international clinical sites to support licensing and safer, age-appropriate treatment options.
Who could benefit from this research
Good fit: Ideal participants are pregnant or postpartum people with HIV, infants, children, and adolescents living with HIV, and those with or at risk for TB who receive care at participating IMPAACT sites.
Not a fit: People without HIV or those not able or willing to enroll at an IMPAACT clinical site are unlikely to benefit directly from participation in this program.
Why it matters
Potential benefit: If successful, the program could lead to safer, more durable HIV and TB treatments, better dosing for pregnant people and kids, and potential approaches that allow some children or adolescents to control HIV without lifelong ART.
How similar studies have performed: Past pediatric and maternal HIV trials have successfully improved dosing and safety of antiretrovirals, while ART-free remission strategies remain more experimental and less proven.
Where this research is happening
Baltimore, United States
- Johns Hopkins University — Baltimore, United States (Active)
Researchers
- Principal investigator: Nachman, Sharon a — Johns Hopkins University
- Study coordinator: Nachman, Sharon a
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.